Gland Pharma Share Price
(GLAND)
Check the latest share price of Gland Pharma, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
as on 04:01PM, 02 May 2025
NSE
Gland Pharma Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹1,382.3Day's Price Range₹1,421.652 Week's Low
52 Week's High
₹1,277.852-Week Price Range₹2,220.95
| Returns % | |
| 1 Month Return | -10 % |
| 3 Month Return | -7.3 % |
| 1 Year Return | -16.78 % |
| Market Stats | |
| Previous Close | ₹1,400.00 |
| Open | ₹1,400.00 |
| Volume | 1.05L |
| Upper Circuit | ₹1,680.00 |
| Lower Circuit | ₹1,120.00 |
| Market Cap | ₹23,123.56Cr |
Gland Pharma Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹23,123.56 Cr
Return on Equity (ROE)
12.31
PE Ratio (TTM)
32.82
Return on capital employed (ROCE)
16.65
Beta (LTM)
0.73
P/B Ratio
3.37
Dividend Yield
1.09
PEG Ratio
11.89
EPS (TTM)
46.9
Sector
Pharmaceuticals
Technical Analysis
Bearish
View Technical Analysis
How to invest in Gland Pharma
Investing in Gland Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Gland Pharma or GLAND on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Gland Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Gland Pharma with just a few clicks!
Gland Pharma Valuation
Track how the P/E of Gland Pharma has moved over time to understand valuation trends.
Gland Pharma in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (32.82x)
May 2, 2025
Industry (54.34x)
May 2, 2025
Highest (67.14x)
August 12, 2021
Today’s Price to Earnings Ratio: 32.82x
Analysts Recommendation on Gland Pharma
Get updated buy, sell, and hold recommendations by analysts on Gland Pharma.
based on 11 analysts
41.67%
Buy
8.33%
Hold
50.00%
Sell
50% of analysts recommend a 'HOLD' rating for Gland Pharma. Average target price of ₹1712.91
Source: S&P Global Market Intelligence
Analysts Forecast on Gland Pharma
Get share price movements and forecasts by analysts on Gland Pharma.
Gland Pharma price forecast by 11 analysts
Upside of22.05%
High
₹3120
Target
₹1712.91
Low
₹1162
Gland Pharma target price ₹1712.91, a slight upside of 22.05% compared to current price of ₹1403.5. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma revenue growth forecast
Expected growth rate Q1, FY2027:26.24%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma EPS growth forecast
EPS estimate Q1, FY2027:50.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Financials
Get the annual and quarterly financial summary of Gland Pharma, including revenue, profit, loss and more.
Gland Pharma Index Inclusions
Gland Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Gland Pharma.
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit jumped 6.69% since last year same period to ₹204.69Cr in the Q3 2024-2025. On a quarterly growth basis, Gland Pharma Ltd has generated 25.17% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Gland Pharma Ltd has declared dividend of ₹20 - translating a dividend yield of 1.43%.
Read More about Dividends
Gland Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Gland Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 6.9% | 0.00 | |
| Mutual Funds | 31.16% | 0.00 | |
| Retail Investors | 7.99% | 0.00 | |
| Others | 2.11% | 0.00 |
Gland Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Gland Pharma with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹23,123.56 Cr | -4.57% | 0.50 | ₹772 Cr | ₹5,664 Cr | |
| HOLD | ₹1,62,042.02 Cr | 33.38% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,10,165.81 Cr | 34.8% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹38,287.13 Cr | -2.18% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| BUY | ₹1,23,213.62 Cr | 29.87% | 0.50 | ₹4,155 Cr | ₹25,774 Cr |
Gland Pharma News & Key Events
Latest news and events at one place to help you take investing decisions in Gland Pharma.
Gland Pharma Secures USFDA Approval for Eye Drug - 30 Apr, 2025
Gland Pharma has received USFDA approval for its Latanoprostene Bunod Ophthalmic Solution, a generic equivalent to VYZULTA, allowing 180 days of exclusivity. The product targets high eye pressure in glaucoma patients and had US sales of approximately $171 million in the past year.Gland Pharma Updates RTA Contact Details Post-Rebranding - 24 Apr, 2025
Gland Pharma Limited has updated the contact details of its Registrar and Share Transfer Agent, rebranding from Link Intime India Private Limited to MUFG Intime India Private Limited. This change is essential for shareholders and stakeholders for effective communication and service requests.Gland Pharma Secures SEBI Compliance Certificate - 10 Apr, 2025
Gland Pharma Limited announced the receipt of a SEBI compliance certificate for Q1 2025, ensuring transparency and regulatory adherence. However, the stock has faced recent declines alongside broader market pressures.Gland Pharma Overview: Market Position and Performance - 05 Apr, 2025
Gland Pharma Ltd specializes in injectable formulations and complex drug molecules. With a market cap of Rs 24,306 crores, its PE ratio is lower than the industry average. The stock is down 33% from its 52-week high of Rs 2,220.95, currently at Rs 1,475. ROE and ROCE stand at 9.26% and 13.58%, respectively.Gland Pharma Shares Decline Amid Tariff Concerns - 04 Apr, 2025
Gland Pharma shares fell 5.29% to ₹1,477.00 following President Trump's hints at potential pharmaceutical tariffs. Analysts warn this could pressure margins and impact revenue from the U.S. market.Gland Pharma Gains on Tariff Exemption and FDA Approval - 03 Apr, 2025
Gland Pharma's stock saw positive movement following USFDA approval for Acetaminophen Injection and tariff exemptions for pharmaceuticals, boosting investor confidence.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 5.04% to 6.90% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 143.76 Cr → 204.69 Cr (in ₹), with an average increase of 16.1% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 196.9%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 54.5% return, outperforming this stock by 71.3%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 1.46K Cr → 1.44K Cr (in ₹), with an average decrease of 1.6% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 years, GLAND stock has moved down by -55.1%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 8.33% to 7.99% in Mar 2025 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 32.37% to 31.16% in Mar 2025 quarter
About Gland Pharma
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Revenue: ₹1,384.05Cr as on December 2024 (Q4 24)
Net Profit: ₹204.69Cr as on December 2024 (Q4 24)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Gland Pharma
Check out the Mutual Funds with significant holdings in Gland Pharma.
FAQs
What is Gland Pharma Ltd price today?
Gland Pharma Ltd share price today stands at ₹1403.5, Open: ₹1400, Previous Close: ₹1400, High: ₹1421.6, Low: ₹1382.3, 52 Week High: ₹2220.95, 52 Week Low: ₹1277.8.
How to Buy Gland Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Gland Pharma Ltd shares
What are today's traded volumes of Gland Pharma Ltd?
Today's traded volume of Gland Pharma Ltd(GLAND) is 1.05L.
What is today's market capitalisation of Gland Pharma Ltd?
Today's market capitalisation of Gland Pharma Ltd(GLAND) is ₹23,123.56 Cr.
What is the 52 Week High and Low Range of Gland Pharma Ltd?
How much percentage Gland Pharma Ltd is down from its 52 Week High?
Gland Pharma Ltd (GLAND) share price is ₹1403.5. It is down -36.81% from its 52 Week High price of ₹2220.95
How much percentage Gland Pharma Ltd is up from its 52 Week low?
Gland Pharma Ltd (GLAND) share price is ₹1403.5. It is up 9.84% from its 52 Week Low price of ₹1277.8